
UCB
UCB | BR
Overview
Corporate Details
- ISIN(s):
- BE0002730118 (+5 more)
- LEI:
- 2138008J191VLSGY5A09
- Country:
- Belgium
- Address:
- ALLÉE DE LA RECHERCHE 60, 1070 ANDERLECHT
- Website:
- https://www.ucb.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
A global biopharma company, inspired by the needs of people living with severe diseases. At UCB, we are consistently delivering on our commitment to improve the lives of people living with severe neurological and immunological conditions. And thanks to our focused, innovative and trusted solutions, our business is strong. Our people have lived our purpose each day since 1928, making critical investments in biopharmaceutical research and leading innovations that strive to achieve a meaningful impact on the lives of those we serve. UCB’s ambition is to transform the lives of people living with severe diseases, allowing them to live the best life that they can – as free as possible from the challenges and uncertainty of disease. That commitment comes to life in our research and development activities across neurology, immunology and other areas where our expertise, innovation and ambition align with unmet needs.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-08-12 20:00 |
Major Shareholding Notification
EN PR.pdf
|
English | 307.0 KB | |
2025-08-12 20:00 |
Major Shareholding Notification
FR PR.pdf
|
French | 294.4 KB | |
2025-08-12 20:00 |
Major Shareholding Notification
NL PR.pdf
|
Dutch | 289.3 KB | |
2025-07-31 07:00 |
Interim Report
UCB PR HY 2025 ENG.pdf
|
English | 615.4 KB | |
2025-07-31 07:00 |
Earnings Release
UCB PR HY 2025 FR.pdf
|
French | 590.2 KB | |
2025-07-31 07:00 |
Interim Report
UCB PR HY 2025 NL.pdf
|
Dutch | 983.3 KB | |
2025-07-31 07:00 |
Interim Report
UCB_Half-Year_2025_Report-EN-FINAL.pdf
|
English | 1.5 MB | |
2025-07-31 07:00 |
Interim Report
UCB_Half-Year_2025_Report-FR-FINAL.pdf
|
French | 1.5 MB | |
2025-07-31 07:00 |
Interim Report
UCB_Half-Year_2025_Report-NL-FINAL.pdf
|
Dutch | 1.5 MB | |
2025-07-10 20:00 |
Major Shareholding Notification
EN FMR 10.07.2025.pdf
|
English | 348.5 KB | |
2025-07-10 20:00 |
Major Shareholding Notification
FR FMR 10.07.2025.pdf
|
French | 304.0 KB | |
2025-07-10 20:00 |
Major Shareholding Notification
NL FMR 10.07.2025.pdf
|
Dutch | 304.0 KB | |
2025-07-08 20:00 |
Major Shareholding Notification
EN Transparency BR.pdf
|
English | 292.5 KB | |
2025-07-08 20:00 |
Major Shareholding Notification
FR Transparency BR.pdf
|
French | 294.4 KB | |
2025-07-08 20:00 |
Major Shareholding Notification
NL Transparency BR.pdf
|
Dutch | 299.5 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
2025-04-28 | Caeymaex Emmanuel | Executive member | Sell | 2,597 | 389,420.15 EUR |
2025-04-22 | Peacock Jonathan | Board | Buy | 674 | 93,247.90 EUR |
2025-04-01 | Lund- Jürgensen Kirsten | Executive member | Buy | 2,143 | N/A |
2025-03-04 | Caeymaex Emmanuel | Executive member | Sell | 7,000 | 1,362,568.51 EUR |
2025-03-04 | Caeymaex Emmanuel | Executive member | Buy | 7,000 | 532,630.00 EUR |
2025-03-03 | Caeymaex Emmanuel | Executive member | Sell | 4,100 | 769,226.28 EUR |
2025-03-03 | Caeymaex Emmanuel | Executive member | Sell | 2,822 | 522,643.25 EUR |
2025-03-03 | Caeymaex Emmanuel | Executive member | Buy | 4,100 | 271,338.00 EUR |
2025-03-03 | Caeymaex Emmanuel | Executive member | Buy | 2,822 | 198,273.72 EUR |
2025-02-28 | Caeymaex Emmanuel | Executive member | Sell | 7,000 | 1,260,465.07 EUR |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
![]() |
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
![]() |
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
Alma Yesodot Ltd. | Israel | KVSR | ||
![]() |
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
Ananda Pharma Plc | United Kingdom | N/A | ||
![]() |
AnGes, Inc. | Japan | 4563 |